Trials / Conditions / Relapsed or Refractory Chronic Lymphocytic Leukemia

Relapsed or Refractory Chronic Lymphocytic Leukemia

7 registered clinical trials studyying Relapsed or Refractory Chronic Lymphocytic Leukemia — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for NCT05963217	University Health Network, Toronto	Phase 1
Terminated	Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, NCT03755154	Institut de Recherches Internationales Servier	Phase 1
Completed	CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL NCT03739554	Cyclacel Pharmaceuticals, Inc.	Phase 1
Active Not Recruiting	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory C NCT03734198	French Innovative Leukemia Organisation	Phase 2
Completed	Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic L NCT03206918	BeiGene	Phase 2
Completed	A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lym NCT01578707	Pharmacyclics LLC.	Phase 3
Completed	Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocy NCT00963105	Celgene	Phase 2